Hanmi formulations deal set to extend GSK's emerging markets reach
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is continuing its push into emerging markets through a new alliance with the South Korean firm Hanmi Pharm that will focus on the co-development and global commercialisation of "evidence-based formulations".